Celcuity's Gedatolisib Phase 3 Trial Achieves Primary Endpoint in PIK3CA Mutant Breast Cancer
Summary
Celcuity reported positive Phase 3 trial results for gedatolisib in PIK3CA mutant breast cancer, showing significant improvement in progression-free survival and paving the way for an sNDA submission.
Key Events
-
Positive Phase 3 Trial Results
The PIK3CA mutant cohort of the VIKTORIA-1 trial for gedatolisib achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of care.
-
Expanded Market Potential
This success in the PIK3CA mutant population significantly broadens the addressable market for gedatolisib, complementing the existing FDA Priority Review for the PIK3CA wild-type cohort.
-
Planned sNDA Submission
Celcuity intends to submit these positive data to the FDA as a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting.
-
Favorable Safety Profile
Both gedatolisib regimens were generally well tolerated with manageable safety profiles and no new safety signals.
Analysis
Celcuity Inc. announced highly positive topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib. The drug demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in both triplet and doublet regimens, with a manageable safety profile. This success significantly expands the potential market for gedatolisib, building on the existing FDA Priority Review for the PIK3CA wild-type cohort. The company plans to submit these data for a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting, marking a critical step towards broader commercialization and addressing a significant unmet medical need in advanced breast cancer.
At the time of this filing, CELC was trading at $140.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $9.51 to $129.09. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.